Valeant Must Face Deceptive Pricing Claims By Hedge Funds
A New Jersey federal judge has refused to toss claims in a hedge fund group's lawsuit accusing Valeant Pharmaceuticals International Inc. of duping investors about the sustainability of its business model,...To view the full article, register now.
Already a subscriber? Click here to view full article